[go: up one dir, main page]

WO2018134681A8 - Anticorps anti-tgf-bêta et leur utilisation - Google Patents

Anticorps anti-tgf-bêta et leur utilisation Download PDF

Info

Publication number
WO2018134681A8
WO2018134681A8 PCT/IB2018/000088 IB2018000088W WO2018134681A8 WO 2018134681 A8 WO2018134681 A8 WO 2018134681A8 IB 2018000088 W IB2018000088 W IB 2018000088W WO 2018134681 A8 WO2018134681 A8 WO 2018134681A8
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
antibody
beta antibodies
conditions
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/000088
Other languages
English (en)
Other versions
WO2018134681A1 (fr
Inventor
Gary Shapiro
Kevin BROWER
Patrick Finn
Richard C. GREGORY
Rao KODURI
Feng Liu
Natalia MALKOVA
Parminder MANKOO
Jack R. POLLARD
Huawei Qiu
Joachim Theilhaber
Christopher Winter
Marcella Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CR20190375A priority Critical patent/CR20190375A/es
Priority to CA3050845A priority patent/CA3050845A1/fr
Priority to EP18711394.9A priority patent/EP3571227A1/fr
Priority to JP2019539214A priority patent/JP7213186B2/ja
Priority to MYPI2019003989A priority patent/MY200751A/en
Priority to AU2018209391A priority patent/AU2018209391B2/en
Priority to IL268112A priority patent/IL268112B2/en
Priority to CN201880007975.3A priority patent/CN110520441B8/zh
Priority to MX2019008551A priority patent/MX2019008551A/es
Priority to BR112019014787-0A priority patent/BR112019014787A2/pt
Priority to PE2019001465A priority patent/PE20200734A1/es
Priority to NZ756431A priority patent/NZ756431B2/en
Priority to KR1020237027750A priority patent/KR102699080B1/ko
Priority to EA201991729A priority patent/EA201991729A1/ru
Priority to SG11201906660TA priority patent/SG11201906660TA/en
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to CN202311230922.7A priority patent/CN117417939A/zh
Priority to KR1020197024043A priority patent/KR102568885B1/ko
Priority to KR1020247028042A priority patent/KR20240133763A/ko
Publication of WO2018134681A1 publication Critical patent/WO2018134681A1/fr
Priority to ZA2019/04494A priority patent/ZA201904494B/en
Priority to PH12019501635A priority patent/PH12019501635A1/en
Anticipated expiration legal-status Critical
Priority to CONC2019/0008946A priority patent/CO2019008946A2/es
Publication of WO2018134681A8 publication Critical patent/WO2018134681A8/fr
Priority to JP2023003484A priority patent/JP7411832B2/ja
Priority to JP2023216508A priority patent/JP2024038040A/ja
Priority to IL311866A priority patent/IL311866B1/en
Priority to AU2024264593A priority patent/AU2024264593A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps pan-TGF-β amélioré pour le traitement d'états pathologiques qui sont induits par le TGF-β, notamment des maladies auto-immunes, des états pathologiques fibrotiques et des cancers. L'invention concerne également des procédés et des utilisations de l'anticorps conjointement avec d'autres agents immunomodulateurs, tels qu'un anticorps anti-PD-1.
PCT/IB2018/000088 2017-01-20 2018-01-19 Anticorps anti-tgf-bêta et leur utilisation Ceased WO2018134681A1 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SG11201906660TA SG11201906660TA (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use
EP18711394.9A EP3571227A1 (fr) 2017-01-20 2018-01-19 Anticorps anti-tgf-bêta et leur utilisation
JP2019539214A JP7213186B2 (ja) 2017-01-20 2018-01-19 抗ｔｇｆベータ抗体およびそれらの使用
MYPI2019003989A MY200751A (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use
AU2018209391A AU2018209391B2 (en) 2017-01-20 2018-01-19 Anti-TGF-beta antibodies and their use
IL268112A IL268112B2 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use
CN201880007975.3A CN110520441B8 (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途
MX2019008551A MX2019008551A (es) 2017-01-20 2018-01-19 Anticuerpos anti-tgf-beta y su uso.
BR112019014787-0A BR112019014787A2 (pt) 2017-01-20 2018-01-19 Anticorpos anti-tgf-beta e seu uso
PE2019001465A PE20200734A1 (es) 2017-01-20 2018-01-19 Anticuerpos anti-tgf-beta y su uso
NZ756431A NZ756431B2 (en) 2018-01-19 Anti-tgf-beta antibodies and their use
KR1020237027750A KR102699080B1 (ko) 2017-01-20 2018-01-19 항-tgf-베타 항체 및 이의 용도
EA201991729A EA201991729A1 (ru) 2017-01-20 2018-01-19 Антитела к tgf-бета и их применение
CR20190375A CR20190375A (es) 2017-01-20 2018-01-19 Anticuerpos anti-tgf-beta y su uso
CN202311230922.7A CN117417939A (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途
CA3050845A CA3050845A1 (fr) 2017-01-20 2018-01-19 Anticorps anti-tgf-beta et leur utilisation
KR1020197024043A KR102568885B1 (ko) 2017-01-20 2018-01-19 항-tgf-베타 항체 및 이의 용도
KR1020247028042A KR20240133763A (ko) 2017-01-20 2018-01-19 항-tgf-베타 항체 및 이의 용도
ZA2019/04494A ZA201904494B (en) 2017-01-20 2019-07-09 Anti¿tgf¿beta antibodies and their use
PH12019501635A PH12019501635A1 (en) 2017-01-20 2019-07-12 Anti-tgf-beta antibodies and their use
CONC2019/0008946A CO2019008946A2 (es) 2017-01-20 2019-08-16 Anticuerpos anti-tgf-beta y su uso
JP2023003484A JP7411832B2 (ja) 2017-01-20 2023-01-13 抗ｔｇｆベータ抗体およびそれらの使用
JP2023216508A JP2024038040A (ja) 2017-01-20 2023-12-22 抗ｔｇｆベータ抗体およびそれらの使用
IL311866A IL311866B1 (en) 2017-01-20 2024-04-01 Anti-TGF-beta antibodies and their use
AU2024264593A AU2024264593A1 (en) 2017-01-20 2024-11-13 Anti-TGF-beta antibodies and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305061.8 2017-01-20
US62/448,800 2017-01-20
EP17305061 2017-01-20
EP1730561.8 2017-01-20

Publications (2)

Publication Number Publication Date
WO2018134681A1 WO2018134681A1 (fr) 2018-07-26
WO2018134681A8 true WO2018134681A8 (fr) 2019-10-10

Family

ID=58018036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/000088 Ceased WO2018134681A1 (fr) 2017-01-20 2018-01-19 Anticorps anti-tgf-bêta et leur utilisation

Country Status (3)

Country Link
EP (1) EP3571227A1 (fr)
EA (1) EA201991729A1 (fr)
WO (1) WO2018134681A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
CA3105333A1 (fr) 2018-07-10 2020-01-16 Sanofi Polytherapies anticancereuses ciblant cd38 et tgf-beta
TW202005981A (zh) 2018-07-11 2020-02-01 美商供石公司 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
EP4087659A2 (fr) 2020-01-11 2022-11-16 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
BR112022013733A2 (pt) 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
EP4121163A1 (fr) * 2020-03-19 2023-01-25 Genentech, Inc. Anticorps anti-tgf-bêta sélectifs d'isoforme et procédés d'utilisation
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022256723A2 (fr) 2021-06-03 2022-12-08 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
EP4370148A1 (fr) 2021-07-14 2024-05-22 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
WO2025240343A1 (fr) 2024-05-13 2025-11-20 Scholar Rock, Inc. Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
ES2763869T3 (es) * 2013-03-20 2020-06-01 Genzyme Corp Métodos para tratar la osteogénesis imperfecta
KR102100419B1 (ko) 2013-09-13 2020-04-14 베이진 스위찰랜드 게엠베하 항-pd1 항체 및 이의 치료 및 진단 용도
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX389663B (es) * 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
ES2820768T3 (es) * 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1

Also Published As

Publication number Publication date
EP3571227A1 (fr) 2019-11-27
EA201991729A1 (ru) 2019-12-30
WO2018134681A1 (fr) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
WO2018134681A8 (fr) Anticorps anti-tgf-bêta et leur utilisation
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
MX2020013169A (es) Conjugados de camptotecina.
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
PH12020552229A1 (en) Il-11ra antibodies
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP3486256A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
MX2025000260A (es) Proteina de union al antigeno anti-steap1
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3964527A3 (fr) Polythérapie contre le cancer
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
MX2017001599A (es) Anticuerpos novedosos y sus usos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
WO2018046997A3 (fr) Anticorps synthétiques contre le vegf et leurs utilisations
AU2018279184A1 (en) Anti-TrkB antibodies
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.
WO2019126594A3 (fr) Anticorps dirigés contre la centrine-1, leurs procédés de fabrication et leurs utilisations
EP4257195A3 (fr) Anticorps anti-cfae et méthodes d'utilisation
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18711394

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3050845

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019539214

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019014787

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197024043

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2019/0008946

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2019000418

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2018209391

Country of ref document: AU

Date of ref document: 20180119

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018711394

Country of ref document: EP

Effective date: 20190820

WWP Wipo information: published in national office

Ref document number: NC2019/0008946

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112019014787

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190718

WWG Wipo information: grant in national office

Ref document number: 201880007975.3

Country of ref document: CN

WWR Wipo information: refused in national office

Ref document number: NC2019/0008946

Country of ref document: CO

WWG Wipo information: grant in national office

Ref document number: 756431

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020247028042

Country of ref document: KR

WWD Wipo information: divisional of initial pct application

Ref document number: 323799

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: 1020247028042

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020247028042

Country of ref document: KR